Mirum Pharmaceuticals (MIRM) Net Cash Flow (2019 - 2026)

Mirum Pharmaceuticals' Net Cash Flow history runs 8 years deep, the most recent figure standing at $29.7 million for Q1 2026.

• In Q1 2026, Net Cash Flow rose 353.47% year-over-year to $29.7 million; the TTM figure through Mar 2026 stood at $113.5 million (up 225.77% YoY), while the FY2025 annual figure was $72.0 million, up 215.96% from the prior year.
• Net Cash Flow for Q1 2026 stood at $29.7 million, up from $16.1 million in the prior quarter.
• The five-year high for Net Cash Flow was $147.9 million in Q2 2023, with the low at -$69.2 million in Q2 2024.
• The 5-year median for Net Cash Flow is $9.0 million (2022), against an average of $11.5 million.
• The sharpest annual moves came in 2024 and 2025: Net Cash Flow sank 265.78% in 2024, then soared 1660.35% in 2025.
• Mirum Pharmaceuticals' Net Cash Flow stood at -$7.8 million in 2022, then slumped by 114.78% to -$16.8 million in 2023, then soared by 105.42% to $913000.0 in 2024, then jumped by 1660.35% to $16.1 million in 2025, then surged by 85.09% to $29.7 million in 2026.
• Business Quant data shows MIRM's Net Cash Flow at $29.7 million in Q1 2026, $16.1 million in Q4 2025, and $53.6 million in Q3 2025.